Conflict of interest
MP, MM
ENDO, EMD
Authors RG and JL were employed by the company Pfizer. Authors RL, AY, and DT-B were employed by the company Adelphi Values. MM reports being an advisory board member for BioMarin, Ferring, Merck, Novo Nordisk, Pfizer, and Sandoz; receiving consulting fees from BioMarin, Merck, Novo Nordisk, Pfizer, and Sandoz; receiving grants from Merck and Pfizer; and being a speaker for Ascendis, BioMarin, Merck, Novo Nordisk, Pfizer, and Sandoz. BM reports being an advisory board member for Ascendis, BioMarin, EMD Serono, Endo Pharmaceuticals, Novo Nordisk, Pfizer, Provention Bio and Tolmar; receiving consulting fees from Ascendis, BioMarin, EMD Serono, Endo Pharmaceuticals, Novo Nordisk, Pfizer, and Tolmar; being a research investigator for AbbVie, Aeterna Zentaris, Alexion, Amicus, Lumos, Novo Nordisk, OPKO Health, and Pfizer; and being a speaker for BioMarin, Novo Nordisk, Pfizer and Tolmar. MP reports being an advisory board member for Ipsen, Novo Nordisk, and Pfizer; receiving consulting fees from Ipsen, Novo Nordisk, and Pfizer; being a research investigator for Ipsen, Merck, Novo Nordisk, Pfizer, Sandoz, and Sanofi; and being a speaker for Ipsen and Novo Nordisk.The authors declare that this study received funding from Pfizer. Pfizer developed the study protocol, study documents, and survey questionnaire in collaboration with Adelphi Values. Medical writing support for this article was funded by Pfizer. The authors had final authority, including on the choice of journal, on all aspects of the manuscript content and development.